ICML 2019 | Here’s looking at you: CLL research to watch
Barbara Eichhorst
• 20 Jun 2019
Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the chronic lymphocytic leukemia (CLL) studies to watch out for in the lead-up to and beyond the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition. Dr Eichhorst highlights the FLAIR trial of ibrutinib-containing regimens, including ibrutinib and venetoclax, in the frontline setting (ISRCTN01844152). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
